Multiple myeloma is affected by multiple and heterogeneous somatic mutations in adhesion- and receptor tyrosine kinase signaling molecules

Blood Cancer Journal

Volumn 3, Issue 2, 2013, Pages

  Leich, E ^a   Weibach, S ^a   Klein, H U ^b   Grieb, T ^a   Pischimarov, J ^a   Stuhmer, T ^a   Chatterjee, M ^a   Steinbrunn, T ^a   Langer, C ^c   Eilers, M ^d   Knop, S ^a   Einsele, H ^a   Bargou, R ^a   Rosenwald, A ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b UNIVERSITY OF MÜNSTER   (Germany)

^c UNIVERSITY HOSPITAL ULM   (Germany)

^d UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

Adhesion; Multiple Myeloma; Receptor Tyrosine Kinases; Somatic Mutations; Whole Exome Sequencing

Indexed keywords

PROTEIN TYROSINE KINASE;

ARTICLE; CELL ADHESION; CLINICAL ARTICLE; EXOME; HUMAN; HUMAN CELL; MOLECULAR INTERACTION; MULTIPLE MYELOMA; SOMATIC MUTATION; TUMOR MICROENVIRONMENT;

EID: 84878339471     PISSN: None     EISSN: 20445385     Source Type: Journal    
DOI: 10.1038/bcj.2012.47     Document Type: Article

References (37)

1. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri S, Stein H et al. WHO Classification of Tumors of Haematopoietic and Lymphoid TissuesIARC: Lyon, 2008.
2. Palumbo A, Anderson K. Multiple myeloma. N Engl J Med 2011; 364: 1046-1060.
3. Chesi M, Bergsagel PL. Many multiple myelomas: Making more of the molecular mayhem. Hematology Am Soc Hematol Educ Program 2011; 2011: 344-353.
4. Bergsagel PL, Kuehl WM. Molecular pathogenesis and a consequent classification of multiple myeloma. J Clin Oncol 2005; 23: 6333-6338. (Pubitemid 46218843)
5. Chapman MA, Lawrence MS, Keats JJ, Cibulskis K, Sougnez C, Schinzel AC et al. Initial genome sequencing and analysis of multiple myeloma. Nature 2011; 471: 467-472.
6. Egan JB, Shi CX, Tembe W, Christoforides A, Kurdoglu A, Sinari S et al. Whole genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution and clonal tides. Blood 2012; 120: 1060-1066.
7. Walker BA, Wardell CP, Melchor L, Hulkki S, Potter NE, Johnson DC et al. Intraclonal heterogeneity and distinct molecular mechanisms characterize the development of t(4;14) and t(11;14) myeloma. Blood 2012; 120: 1077-1086.
8. Bommert K, Bargou RC, Stuhmer T. Signalling and survival pathways in multiple myeloma. Eur J Cancer 2006; 42: 1574-1580. (Pubitemid 44118772)
9. Klein B, Tarte K, Jourdan M, Mathouk K, Moreaux J, Jourdan E et al. Survival and proliferation factors of normal and malignant plasma cells. Int J Hematol 2003; 78: 106-113. (Pubitemid 37021949)
10. Lentzsch S, Chatterjee M, Gries M, Bommert K, Gollasch H, Dorken B et al. PI3-K/ AKT/FKHR and MAPK signaling cascades are redundantly stimulated by a variety of cytokines and contribute independently to proliferation and survival of multiple myeloma cells. Leukemia 2004; 18: 1883-1890. (Pubitemid 39530020)
11. Tai YT, Podar K, Catley L, Tseng YH, Akiyama M, Shringarpure R et al. Insulin-like growth factor-1 induces adhesion and migration in human multiple myeloma cells via activation of beta1-integrin and phosphatidylinositol 3'-kinase/ AKT signaling. Cancer Res 2003; 63: 5850-5858. (Pubitemid 37187484)
12. Yaccoby S, Wezeman MJ, Henderson A, Cottler-Fox M, Yi Q, Barlogie B et al. Cancer and the microenvironment: Myeloma-osteoclast interactions as a model. Cancer Res 2004; 64: 2016-2023. (Pubitemid 38339448)
13. Stuhmer T, Arts J, Chatterjee M, Borawski J, Wolff A, King P et al. Preclinical antimyeloma activity of the novel HDAC-inhibitor JNJ-26481585. Br J Haematol 2010; 149: 529-536.
14. Liebisch P, Dohner H. Cytogenetics and molecular cytogenetics in multiple myeloma. Eur J Cancer 2006; 42: 1520-1529. (Pubitemid 44118770)
15. Ross F, Avet-Loiseau H, Ameye G, Gutierrez NC, Liebisch P, OC S et al. Report from the european myeloma network on interphase FISHin multiple myeloma and related disorders. Haematologica 2012; 97: 1272-1277.
16. DePristo MA, Banks E, Poplin R, Garimella KV, Maguire JR, Hartl C et al. A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nat Genet 2011; 43: 491-498.
17. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 2005; 102: 15545-15550. (Pubitemid 41528093)
18. Szklarczyk D, Franceschini A, Kuhn M, Simonovic M, Roth A, Minguez P et al. The STRING database in 2011: Functional interaction networks of proteins, globally integrated and scored. Nucleic Acids Res 2011; 39(Database issue): D561-D568.
19. Bergsagel PL. Impressions of the myeloma landscape. Blood 2010; 116: 2403-2404.
20. Kumar SK, Mikhael JR, Buadi FK, Dingli D, Dispenzieri A, Fonseca R et al. Management of newly diagnosed symptomatic multiple myeloma: Updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines. Mayo Clin Proc 2009; 84: 1095-1110.
21. Pineda-Roman M, Zangari M, Haessler J, Anaissie E, Tricot G, van Rhee F et al. Sustained complete remissions in multiple myeloma linked to bortezomib in total therapy 3: Comparison with total therapy 2. Br J Haematol 2008; 140: 625-634. (Pubitemid 351300910)
22. Tiacci E, Trifonov V, Schiavoni G, Holmes A, Kern W, Martelli MP et al. BRAF mutations in hairy-cell leukemia. N Engl J Med 2011; 364: 2305-2315.
23. Ocio EM, Mateos MV, Maiso P, Pandiella A, San-Miguel JF. New drugs in multiple myeloma: Mechanisms of action and phase I/II clinical findings. Lancet Oncol 2008; 9: 1157-1165.
24. Zhou Y, Barlogie B, Shaughnessy Jr. JD. The molecular characterization and clinical management of multiple myeloma in the post-genome era. Leukemia 2009; 23: 1941-1956.
25. Chatterjee M, Stuhmer T, Herrmann P, Bommert K, Dorken B, Bargou RC. Combined disruption of both the MEK/ERK and the IL-6R/STAT3 pathways is required to induce apoptosis of multiple myeloma cells in the presence of bone marrow stromal cells. Blood 2004; 104: 3712-3721. (Pubitemid 39564449)
26. Hideshima T, Bergsagel PL, Kuehl WM, Anderson KC. Advances in biology of multiple myeloma: Clinical applications. Blood 2004; 104: 607-618. (Pubitemid 38970551)
27. Burger JA. Chemokines and chemokine receptors in chronic lymphocytic leukemia (CLL): From understanding the basics towards therapeutic targeting. Semin Cancer Biol 2010; 20: 424-430.
28. Steinbrunn T, Stuhmer T, Gattenlohner S, Rosenwald A, Mottok A, Unzicker C et al. Mutated RAS and constitutively activated Akt delineate distinct oncogenic pathways, which independently contribute to multiple myeloma cell survival. Blood 2011; 117: 1998-2004.
29. Zollinger A, Stuhmer T, Chatterjee M, Gattenlohner S, Haralambieva E, Mu? ller-Hermelink HK et al. Combined functional and molecular analysis of tumor cell signaling defines 2 distinct myeloma subgroups: Akt-dependent and Akt-independent multiple myeloma. Blood 2008; 112: 3403-3411.
30. Awada A, Bozovic-Spasojevic I, Chow L. New therapies in HER2-positive breast cancer: A major step towards a cure of the disease? Cancer Treat Rev 2012; 38: 494-504.
31. Wang L, McLeod HL, Weinshilboum RM. Genomics and drug response. N Engl J Med 2011; 364: 1144-1153.
32. Begnami MD, Fukuda E, Fregnani JH, Nonogaki S, Montagnini AL, da Costa Jr. WL et al. Prognostic implications of altered human epidermal growth factor receptors (HERs) in gastric carcinomas: HER2 and HER3 are predictors of poor outcome. J Clin Oncol 2011; 29: 3030-3036.
33. Friedlander TW, Weinberg VK, Huang Y, Mi JT, Formaker CG, Small EJ et al. A phase II study of insulin-like growth factor receptor inhibition with nordihydroguaiaretic acid in men with non-metastatic hormone-sensitive prostate cancer. Oncol Rep 2012; 27: 3-9.
34. Juergens H, Daw NC, Geoerger B, Ferrari S, Villarroel M, Aerts I et al. Preliminary efficacy of the anti-insulin-like growth factor type 1 receptor antibody figitumumab in patients with refractory Ewing sarcoma. J Clin Oncol 2011; 29: 4534-4540.
35. Maki RG. Small is beautiful: Insulin-like growth factors and their role in growth, development, and cancer. J Clin Oncol 2010; 28: 4985-4995.
36. Pappo AS, Patel SR, Crowley J, Reinke DK, Kuenkele KP, Chawla SP et al. R1507, a monoclonal antibody to the insulin-like growth factor 1 receptor, in patients with recurrent or refractory Ewing sarcoma family of tumors: Results of a phase II Sarcoma Alliance for Research through Collaboration study. J Clin Oncol 2011; 29: 4541-4547.
37. Ramalingam SS, Spigel DR, Chen D, Steins MB, Engelman JA, Schneider CP et al. Randomized phase II study of erlotinib in combination with placebo or R1507, a monoclonal antibody to insulin-like growth factor-1 receptor, for advanced-stage non-small-cell lung cancer. J Clin Oncol 2011; 29: 4574-4580.